Search research articles
Contact Us
Filters
Showing results (151-160 of 234) with videos related to
Page
of 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 6, 2007
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005
Jaap Verweij, Paolo G Casali, Dusan Kotasek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
Anja Henningsson, Sharon Marsh, Walter J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2006
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Martine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2009
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure
Samuel E Deprimo, Xin Huang, Martin E Blackstein, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
July 25, 2009
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn, Inge M Ghobadi Moghaddam-Helmantel, Maja J A de Jonge, et al.
Anti-Cancer Drugs
|
August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
Maja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Cancer Chemotherapy and Pharmacology
|
June 28, 2011
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
Paul Hamberg, Margaret M Woo, Lin-Chi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2003
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors
Hans Gelderblom, Ramon Salazar, Jaap Verweij, et al.
Cancer Chemotherapy and Pharmacology
|
October 20, 2006
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients
Walter J Loos, Ronald de Wit, Steven J Freedman, et al.
Plos One
|
November 8, 2012
Tumor volume as an alternative response measurement for imatinib treated GIST patients
Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 234) with videos related to
Sort By:
Page
of 24
European Journal of Cancer (Oxford, England : 1990)
|
March 6, 2007
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005
Jaap Verweij, Paolo G Casali, Dusan Kotasek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
Anja Henningsson, Sharon Marsh, Walter J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2006
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Martine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2009
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure
Samuel E Deprimo, Xin Huang, Martin E Blackstein, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
July 25, 2009
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn, Inge M Ghobadi Moghaddam-Helmantel, Maja J A de Jonge, et al.
Anti-Cancer Drugs
|
August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
Maja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Cancer Chemotherapy and Pharmacology
|
June 28, 2011
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
Paul Hamberg, Margaret M Woo, Lin-Chi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2003
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors
Hans Gelderblom, Ramon Salazar, Jaap Verweij, et al.
Cancer Chemotherapy and Pharmacology
|
October 20, 2006
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients
Walter J Loos, Ronald de Wit, Steven J Freedman, et al.
Plos One
|
November 8, 2012
Tumor volume as an alternative response measurement for imatinib treated GIST patients
Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, et al.
Page
of 24